Drug intelligence / Profile preview

IL2-Pt@Nanogel

Development stage: Preclinical
Modality: Small Molecules, Hydrogel Systems → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

IL2-Pt@Nanogel is an experimental chemoimmunotherapy nanogel designed for the dual delivery of Interleukin-2 (IL-2) and a platinum-based N-heterocyclic carbene (Pt-NHC) compound. Described in research published in Advanced Functional Materials (2023/2024), this nanoparticle-based system is intended to treat immunologically cold tumors, specifically pancreatic ductal adenocarcinoma (PDAC) and hepatocellular carcinoma (HCC) associated with advanced liver fibrosis. The Pt-NHC component acts as a type II immunogenic cell death (ICD) inducer, while IL-2 serves as a cytokine immunotherapeutic to activate effector T cells. The nanogel works by reducing the immunosuppressive phenotype of tumor-associated macrophages (TAMs), diminishing regulatory T cell (Treg) infiltration, and inducing type I interferon production. Preclinical studies have also explored its use in combination with losartan to further reduce desmoplasia and enhance the immunostimulatory state of the tumor microenvironment.

Other names: IL2-Pt nanogelIL-2-Pt nanogelIL 2-Pt nanogel

Targets

IL2RB (IL-2 receptor beta chain)HS/H (Heparan sulfate and heparin)DNA

Beyond the preview

Go deeper on IL2-Pt@Nanogel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IL2-Pt@Nanogel.

Explore the full profile